Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate
cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency …

Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different
immunologically ''hot''tumors. A phase II study revealed good therapeutic activity of …

Simple Summary Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory
bowel diseases that affect the gut and extraintestinal organs. Preliminary evidence has …

The tumor microenvironment (TME) includes immune (T, B, NK, dendritic), stromal,
mesenchymal, endothelial, adipocytic cells, extracellular matrix, and cytokines/chemokines …

Epigenetic alterations (including DNA methylation or miRNAs) influence oncogene/
oncosuppressor gene expression without changing the DNA sequence. Prostate cancer …

Many studies have investigated the potential prognostic and predictive role of PD-L1 in
prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) …

In prostate cancer (PC), the PD-1/PD-L1 axis regulates various signaling pathways and it is
influenced by extracellular factors. Pre-clinical experimental studies investigating the effects …

Primary cutaneous B-cell lymphomas (PCBCLs) account for 25% of all primary cutaneous
lymphomas. Three major types are currently recognized by the WHO classification: primary …

Simple Summary Intravascular lymphoma is a neoplasm with tumor cells localized
exclusively within blood vessel lumina. Most cases are of B-cell origin; only rare cases of NK …

The interaction of programmed death-1 (PD-1) on T lymphocytes with its ligands
Programmed Death Ligand 1 (PD-L1) and Programmed Death Ligand 2 (PD-L2) on tumor …